Stay updated with breaking news from David Berd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said interim results from its ongoing pre-clinical study shows its vaccine against a family of viruses...
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing
The resistant Rhodococcus equi clone, circulating in the US since the 2000s, has been detected in Ireland.
VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices
VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine. BioVaxys recently ent...